New assay kits extend proprietary technology platform into such areas as inflammation, oncology and allergic diseases and include non-specific screening tool for tyrosine kinases
Molecular Devices has announced the launch of seven new assay kits using its proprietary Imap technology and one new kit in the proprietary CatchPoint format.
The Imap kits - Blk, Lyn, Syk, CHK1, CHK2, Rock-II and PTP1B assay kits - all incorporate enzymes from Upstate Biotechnology, a manufacturer of signal transduction products.
The CatchPoint Tyrosine Kinase assay kits are generic plate-based assays used to measure the activity of various tyrosine kinases in the presence of putative drug compounds.
Molecular Devices's Imap technology is rapidly becoming an established assay format for kinase and phosphatase activity.
This series of seven new assays further extends the Imap technology platform into such crucial areas as inflammation, oncology and allergic diseases.
Molecular Devices now offers a total of 17 specific Imap kits as well as an Imap purchase plan to provide assay components to companies investigating proprietary kinases and phosphatases.
The CatchPoint Tyrosine Kinase assay kit was developed as a non-specific screening tool for use with various tyrosine kinases as a secondary assay to further characterise initial HTS results.
"Kinases and phosphatases are screened at all major pharmaceutical companies, and each additional kit in our Imap portfolio builds more utility onto this technology platform.
Our customers have seven more reasons to adopt Imap," stated Stephen Oldfield, vice president of worldwide marketing at Molecular Devices. "While Imap provides a fluorescence polarisation signal, CatchPoint modulates fluorescence intensity.
These diverse fluorescent readout modes leverage Molecular Devices's significant installed base of Analyst and Gemini microplate readers, providing solutions for thousands of researchers at all stages in the drug development pipeline."
